Universität zu Köln

Pallasch, Christian P. ORCID: 0000-0001-5675-6905 and Hallek, Michael (2014). Incorporating Targeted Agents Into Future Therapy of Chronic Lymphocytic Leukemia. Semin. Hematol., 51 (3). S. 235 - 249. PHILADELPHIA: W B SAUNDERS CO-ELSEVIER INC. ISSN 1532-8686

Full text not available from this repository.

Abstract

Treatment of chronic lymphocytic leukemia (CLL) is currently undergoing profound changes. Several monoclonal antibodies (ofatumumab and obinutuzumab), and the first agent targeting essential signaling cascades in CLL (ibrutinib) have recently been approved. Inhibiting the B-cell receptor pathway seems of particular importance in effective targeted therapies of CLL. Here, inhibition of Bruton's tyrosine kinase and phosphatidylinositol 3-kinase delta currently offer the most promising targeted approaches. The clinical course of CLL presents with an impressive heterogeneity. During recent years, the combined use of clinical, biologic, and genetic parameters has allowed characterization of at least three categories of patients': (1) patients with a very mild onset and course; (2) patients with an intermediate prognosis; and (3) patients with an aggressive course of high-risk leukemia. With this background, it becomes increasingly challenging to select the right treatment strategy for each patient. In the present article, we summarize the current therapeutic tools and their combination partner drugs. Moreover, we offer a perspective on how to integrate the novel targeted agents for CLL therapy into sequential treatment approaches. (C) 2014 Published by Elsevier Inc.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Pallasch, Christian P. UNSPECIFIED orcid.org/0000-0001-5675-6905 UNSPECIFIED Hallek, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-434462
DOI:	10.1053/j.seminhematol.2014.05.005
Journal or Publication Title:	Semin. Hematol.
Volume:	51
Number:	3
Page Range:	S. 235 - 249
Date:	2014
Publisher:	W B SAUNDERS CO-ELSEVIER INC
Place of Publication:	PHILADELPHIA
ISSN:	1532-8686
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PREVIOUSLY UNTREATED PATIENTS; PHASE-II TRIAL; MONOCLONAL-ANTIBODY; ANTI-CD20 ANTIBODY; 1ST-LINE THERAPY; CELL SURVIVAL; B-CELLS; FLUDARABINE; RITUXIMAB; ALEMTUZUMAB Multiple languages Hematology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/43446